VALENCIA, Calif., July 20, 2023 (GLOBE NEWSWIRE) -- Nusano, Inc., a company working to stabilize and enable the production of cancer-fighting radioisotopes, today announced participation in two conferences in July 2023. Nusano CEO Chris Lowe will present an overview of the company’s breakthrough radioisotope production platform at the 2nd Annual Targeted Radiopharmaceuticals Summit on July 26 in Boston. Nusano is also presenting two abstracts in oral presentations at the 11th International Conference on Isotopes, in Saskatoon, Saskatchewan, Canada on July 26 and 27.
Additional presentation details:
2nd Annual Targeted Radiopharmaceuticals Summit (Boston)
| TITLE: | Supplying the Fight Against Cancer: Nusano’s Breakthrough Radioisotope Production Platform | ||
| WHO: | Chris Lowe, CEO | ||
| SESSION: | Targeted Radiopharmaceuticals in the US: The Past, the Present & the Future | ||
| WHEN: | Wednesday, July 26, 2023 at 10:00 AM EDT |
11th International Conference on Isotopes (Saskatoon, Sask.)
| ABSTRACT: | Nusano Targetry for the Production of Medical Isotopes | ||
| WHO: | Greg Moffitt, PhD, Director of Target Development | ||
| SESSION: | Accelerator Produced Radioisotopes | ||
| WHEN: | Wednesday, July 26, 2023, 3:00 PM - 4:30 PM CST* | ||
| ABSTRACT: | Alpha Production Routes for Medical Radioisotopes | ||
| WHO: | Richard Sisson, Targetry Nuclear Engineer | ||
| SESSION: | Accelerator Produced Radioisotopes II | ||
| WHEN: | Thursday, July 27, 2023, 9:50 AM - 11:30 AM CST* |
* Concurrent session presentations of 15 minutes, with a question-and-answer period at the end of the session.
About Nusano, Inc.
Nusano is a privately held medical technology company committed to bringing stability and innovation to the rapidly emerging and critically undersupplied medical radioisotopes market. Nusano’s proprietary ion source is smaller and more efficient than existing production methods. This results in significantly greater yields and allows for the simultaneous manufacturing of multiple radioisotopes. Nusano’s technologies will supply the fight against cancer and support diagnostic and therapeutic radiopharmaceutical development. The company’s state-of-the-art production facility opens Q1 2025 in West Valley City, Utah. For more, please visit www.nusano.com.
Contacts:
At Nusano:
Scott Larrivee, Head of PR & Communications, 608-345-6629,
scott.larrivee@nusano.com
Investor Relations:
Joyce Allaire, LifeSci Advisors, LLC, 212-915-2569,
jallaire@lifesciadvisors.com
